Welcome
Albireo is an independent Swedish biotechnology company, which brings unique translational approaches to develop drugs that fulfil unmet medical needs in the gastrointestinal (GI) area. The team has a broad experience in drug development, primarily in the GI area and has an extensive network in the international scientific and clinical communities.
Latest News
2011-12-21
INN for A3309 is ELOBIXIBAT
2011-12-15
An important study evaluating bowel transit with A3309 is published
Go to news archive
Events
JP Morgan, San Francisco, January 2012
UEGW, Stockholm, October 2011
DDW, Chicago, May 2011